JNCE News and Press, Jounce Therapeutics Inc. From 05/05/21

The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Jounce Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q1 2021 Earnings Call May 4, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call Transcript ...

Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Conference Call May 04, 2021 08:00 AM ET Company Participants Malin Deon - Investor Relations Rich Murray - Chief Executive Officer & President Dmitri Wiederschain - Chief Scientific Officer Beth Trehu - Chief Medical Officer Kim Drapkin -...

Jounce Therapeutics (JNCE): Q1 GAAP EPS of -$0.58 beats by $0.01.Revenue of $1.54M misses by $10.27M.Cash, cash equivalents and investments increased to $271.3M.Press Release For further details see: Jounce Therapeutics EPS beats by $0.01, misses on revenue

- Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab - - Ended the quarter with $271.3 million in cash, cash equivalents and investments - - Comp...

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that two trial in progress posters, on the Phase 1 INNA...

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2021 financial result...

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief...

-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature- - JTX-8064’s mechanism of action to reprogram macrophages can bridge innate immune cell activity ...

Today, we peek back in on Jounce Therapeutics for the first time in nearly two years. It seems a good time to revisit this small developmental firm as the company has advanced its pipeline and addressed its current funding needs. A full analysis on Jounce is provided in the paragr...